Swethajit Biswas
About Swethajit Biswas
Swethajit Biswas is a Development Leader in Autologous Cell Therapy at Adaptimmune, specializing in MAGE-A4. He has extensive experience in oncology drug development, having led clinical trials and participated in regulatory discussions for cell therapies targeting solid tumors.
Work at Adaptimmune
Currently, Swethajit Biswas serves as the Development Leader for Autologous Cell Therapy (MAGE-A4) at Adaptimmune. He has been in this role since 2019, focusing on the development of phase 1/2 studies of Adoptive Cell Therapies, specifically TCR T cell therapies, for various solid tumors. His work includes targeting cancers such as sarcoma, head and neck cancer, and hepatocellular carcinoma.
Education and Expertise
Swethajit Biswas completed his DPhil at the University of Oxford from 2004 to 2007, where he studied Renal Cancer Hypoxia Models and Tumor Metabolism using ex vivo and in vivo Magnetic Resonance Spectroscopy (MRS). He also studied at The University of Sheffield, achieving an MB in Medicine from 1991 to 1996. Since 2020, he has been studying at the Royal College of Physicians London, working towards his Fellowship (FRCP).
Background
Before his current position, Swethajit Biswas worked at GlaxoSmithKline Pharma GmbH as Clinical Director in Oncology Drug Development from 2014 to 2019 in London, United Kingdom. He has a background as a clinician-scientist and associate professor in medical oncology, where he served as a principal investigator in phase 1 trials for solid tumors.
Achievements in Clinical Trials
Swethajit Biswas has led a phase 2 trial that combined immunotherapy and small molecules for a rare hematological disease. He has also participated in FDA and EMA meetings to discuss the registration path for a cell therapy targeting solid tumors. His experience includes leading compassionate use programs for Antibody Drug Conjugates in multiple myeloma.
Expertise in Drug Development
Swethajit Biswas possesses expertise in life cycle management, strategy, and indication expansion for Antibody Drug Conjugates. His extensive experience in oncology drug development and clinical trials positions him as a knowledgeable leader in the field of autologous cell therapy.